Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockade
- Revealing PMS2 inhibition as a first-in-class and first-in-pathway strategy to transiently create drug-induced MMR deficiency.
- Demonstrating the translational potential of an oral PMS2 inhibitor that converts murine and human MMR proficient tumor models to an MMR-deficient state and leads to immune-sensitization in syngeneic murine models.
- Highlighting the potential of short-term MMR inhibition to broaden checkpoint inhibitor benefit to patients with MMR-proficient cancers.